Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent Logan

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Haematologica|September 24, 2016
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesAndrew S Artz, Brent Logan, Xiaochun Zhu, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2010
Second unrelated donor hematopoietic cell transplantation for primary graft failureJeffrey Schriber, Manza-A Agovi, Vincent Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Transplantation and Cellular Therapy|January 12, 2026
Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-AnalysisArmin Ghobadi, Theodora Anagnostou, Jacques Azzi, et al.
Transplantation and Cellular Therapy|April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention TrialsMarcelo C Pasquini, Brent Logan, Richard J Jones, et al.
Blood Advances|August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemiaBetty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Haematologica|September 24, 2016
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesAndrew S Artz, Brent Logan, Xiaochun Zhu, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2010
Second unrelated donor hematopoietic cell transplantation for primary graft failureJeffrey Schriber, Manza-A Agovi, Vincent Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Transplantation and Cellular Therapy|January 12, 2026
Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-AnalysisArmin Ghobadi, Theodora Anagnostou, Jacques Azzi, et al.
Transplantation and Cellular Therapy|April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention TrialsMarcelo C Pasquini, Brent Logan, Richard J Jones, et al.
Blood Advances|August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemiaBetty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Pageof 10